Life Sciences Series: VC Spotlight: Changing Biotech Business Models
A wave of generic drugs based on today’s top blockbusters, the expansion of personalized medicine, fundamental healthcare reform in the United States, and the continued globalization of the industry – on top of a global financial crisis – have made the standard biotech business model unsustainable. How can the industry change the ways in which drugs are developed and commercialized? What are the alternative business models? What is the goal (fail early and cheap)? And are investors driving change in behavior? A panel of seasoned investors – VCs, angels, and corporate investors – will reflect on investments made over the last two years and during the 2011 JP Morgan Healthcare Conference, highlighting what life science entrepreneurs should expect ahead. Q&A and networking will provide an opportunity to better understand and form a successful relationship with investors.
Simeon J. George, M.D.
Partner, SR One
Michael J. Finney, Ph.D.
Managing Director, Life Sciences
Changing Biotech Business Models
|When:||Thursday, January 27, 2011
Registration Opens: 3:30pm
Panel Presentation: 4:00pm – 5:30pm
Networking Reception: 5:30pm – 6:30pm
|Where:||South San Francisco Conference Center
255 South Airport Blvd.
South San Francisco, CA
|Parking:||Multiple Lot Options|
|Getting There:||Public Transportation Information|
|Cost:||Pre-registration through January 24
$20 BayBio Members | $40 Non-Members
On-site registration on January 27
$40 BayBio Members | $75 Non-Members
|Attire:||Business attire suggested|